CYP3A4 and rheumatoid arthritis: Importantly, it is insufficiently absorbed due to the extensive metabolism of first-pass enzymes in the liver by cytochrome P450 3A4, which consequently has a very low oral bioavailability in humans and, therefore, is not used in the treatment of RA [45,46].